血管生成,即从已存在的血管中生成新血管。此通路是通过人体中存在的诸多互补和复杂的信号途径调节的。正常情况下,血管生成的相关诱导剂和抑制剂之间保持平衡状态。但对于创伤、缺氧或炎症继发等微环境破坏的条件下,此通路能做出迅速的应答。在各种慢性病理和肿瘤的情况下,血管生成的平衡状态被打破,导致异常的血管生成或新生血管。
血管生成的激活导致促血管生成生长因子(VEGF、PDGF、FGF和TGF等)的释放,这些因子将其受体结合到已有血管内的内皮细胞上,从而诱导PI3K/Akt、Erk1/2、Smad和Notch等多种途径的信号转导,引起内皮细胞增殖和迁移。内皮细胞利用基质金属蛋白酶和整合素来消化细胞外基质,迁移到新的区域,在那里它们延长并形成管子,产生新的血管。
在肿瘤血管生成过程中,癌细胞刺激新血管的形成,为肿瘤输送氧气和营养。随着肿瘤的生长,位于肿瘤中心的细胞缺氧,使得转录因子HIF-1α(缺氧诱导因子-1)稳定表达。该转录因子与HIF-1β结合上调几种促血管生成基因的表达。此外,生长因子信号还刺激HIF-1活性,以维持生长细胞的氧稳态。
*JAK
项目号 | 产品名称 | 规格 | CAS | 包装 | 细胞 | 靶点 | IC50 | Ki | EC50 |
---|---|---|---|---|---|---|---|---|---|
R126338 | Ruxolitinib (INCB018424) | ≥98% | 941678-49-5 | 5mg,25mg,50mg,100mg | 无细胞 | JAK1 | 3.3 nM | ||
JAK2 | 2.8 nM | ||||||||
E129454 | Tofacitinib (CP-690550) Citrate | ≥99% | 540737-29-9 | 10mg,50mg,250mg | JAK1 | 112 nM | |||
JAK2 | 20 nM | ||||||||
JAK3 | 1 nM | ||||||||
A126326 | AZD1480 | ≥98% | 935666-88-9 | 5mg,25mg,100mg | 无细胞 | JAK2 | 0.26 nM | ||
T126330 | Fedratinib (SAR302503, TG101348) | ≥98% | 936091-26-8 | 5mg,25mg,100mg | 无细胞 | JAK2 | 3 nM | ||
J126663 | JANEX-1 | 98% | 202475-60-3 | 5mg,10mg,50mg | JAK3 | 78 μM | |||
W125855 | WHI-P97 | ≥98% | 211555-05-4 | 10mg,50mg | JAK-3 | 0.09 μM | |||
C127224 | CYT387 | ≥98% | 1056634-68-4 | 5mg,10mg,50mg,100mg | JAK1 | 11 nM | |||
JAK2 | 18 nM | ||||||||
T122330 | Tofacitinib | ≥98% (HPLC) | 477600-75-2 | 5mg,25mg,100mg,500mg,1g | 无细胞 | JAK3 | 1 nM | ||
W129459 | WP1066 | ≥98% | 857064-38-1 | 10mg,50mg | HEL细胞 | JAK2 | 2.30 μM | ||
STAT3 | 2.43 μM | ||||||||
T127523 | TG101209 | 98% | 936091-14-4 | 5mg,25mg,100mg | 无细胞 | JAK2 | 6 nM | ||
Flt3 | 25 nM | ||||||||
RET | 17 nM | ||||||||
L126490 | LY2784544 | ≥98% | 1229236-86-5 | 5mg,10mg,50mg | JAK2 | 3 nM | |||
N129609 | NVP-BSK805 2HCl | ≥97% | 1092499-93-8 | 5mg,10mg,50mg | JAK2 | 0.5 nM | |||
B127687 | Baricitinib | ≥99% | 1187594-09-7 | 5mg,10mg,50mg | 无细胞 | JAK1 | 5.9 nM | ||
JAK2 | 5.7 nM | ||||||||
A129464 | AZ 960 | ≥99% | 905586-69-8 | 2mg,5mg,10mg | JAK2 | <3 nM | <0.45 nM | ||
C129474 | CEP-33779 | ≥99% | 1257704-57-6 | 5mg,10mg,50mg | JAK2 | 1.8 nM | |||
W125072 | WHI-P154 | ≥98% | 211555-04-3 | 10mg,50mg | JAK3 | 1.8 μM | |||
X127151 | XL019 | ≥99% | 945755-56-6 | 5mg,25mg | JAK2 | 2.2 nM | |||
S129613 | S-Ruxolitinib (INCB018424) | ≥99% | 941685-37-6 | 5mg,10mg,50mg | JAK1 | 3.3 nM | |||
JAK2 | 2.8 nM | ||||||||
Z129618 | ZM 39923 HCl | ≥98% | 1021868-92-7 | 10mg,50mg,250mg | JAK1 | 4.4 | |||
JAK3 | 7.1 | ||||||||
R171967 | Ruxolitinib phosphate salt | 97% | 1092939-17-7 | 100mg | JAK | ||||
C114054 | 莪术醇 | 分析标准品,≥98% | 4871-97-0 | 20mg |
*EGFR
项目号 | 产品名称 | 规格 | CAS | 包装 | 细胞 | 靶点 | IC50 | Ki |
---|---|---|---|---|---|---|---|---|
L126696 | Lapatinib | ≥99% | 231277-92-2 | 25mg,100mg,250mg,500mg,1g,5g | ErbB2 | 9.2 nM | ||
EGFR | 10.8 nM | |||||||
L193141 | 二甲苯磺酸拉帕替尼 一水合物 | 0.98 | 388082-78-8 | 1g,5g | EGFR | 10.8 nM | ||
ErbB2 | 9.2 nM | |||||||
E129310 | Erlotinib HCl (OSI-744) | ≥99% | 183319-69-9 | 100mg,500mg,1g,5g | 无细胞 | EGFR | 2 nM | |
G125799 | Gefitinib (ZD1839) | ≥99% | 184475-35-2 | 50mg,250mg,1g,5g,25g,100g | NR6wtEGFR | Tyr1173 | 37 nM | |
Tyr992 | 37nM | |||||||
NR6W | Tyr1173 | 26 nM | ||||||
Tyr992 | 57 nM | |||||||
L129338 | 二对甲苯磺酸拉帕替尼(GW-572016) | ≥98% | 388082-77-7 | 25mg,100mg,250mg,500mg,1g | 无细胞 | ErbB2 | 9.2 nM | |
EGFR | 10.8 nM | |||||||
V125180 | Vandetanib (ZD6474) | ≥99% | 443913-73-3 | 25mg,100mg,500mg | 无细胞 | VEGFR2 | 40 nM | |
VEGFR3 | 110 nM | |||||||
EGFR | 500 nM | |||||||
N126132 | Neratinib (HKI-272) | ≥99% | 698387-09-6 | 5mg,25mg,100mg | 无细胞 | ER2 | 59 nM | |
EGFR | 92 nM | |||||||
C125447 | Canertinib (CI-1033) | ≥98% | 267243-28-7 | 10mg,50mg,250mg | EGFR | 1.5 nM | ||
ErbB2 | 9.0 nM | |||||||
A126525 | AG-490 (Tyrphostin B42) | ≥98% | 133550-30-8 | 20mg,50mg,250mg,1g | 无细胞 | EGFR | 0.1 μM | |
C129397 | CP-724714 | ≥99% | 537705-08-1 | 5mg,10mg,25mg,50mg | HER2/ErbB2 | 10 nM | ||
D129347 | Dacomitinib (PF299804, PF299) | ≥99% | 1110813-31-4 | 5mg,10mg,50mg,250mg | EGFR | 6 nM | ||
W127713 | WZ4002 | ≥98% | 1213269-23-8 | 10mg,50mg,100mg | BaF3细胞系 | EGFR(L858R) | 2 nM | |
EGFR(T790M) | 8 nM | |||||||
A129380 | AZD8931 (Sapitinib) | ≥98% | 848942-61-0 | 5mg,10mg,50mg | 无细胞 | EGFR | 4 nM | |
ErbB2 | 3 nM | |||||||
ErbB3 | 4 nM | |||||||
C127191 | CUDC-101 | ≥98% | 1012054-59-9 | 10mg,25mg,50mg,100mg,250mg | HDAC | 4.4 nM | ||
EGFR | 2.4 nM | |||||||
HER2 | 15.7 nM | |||||||
A126582 | AG-1478 (Tyrphostin AG-1478) | ≥98% | 153436-53-4 | 5mg,10mg,25mg,50mg | 无细胞 | EGFR | 3 nM | |
P129384 | PD153035 HCl | ≥98%(HPLC) | 183322-45-4 | 10mg,50mg,250mg | 无细胞 | EGFR | 29 pM | 5.2 pM |
P125444 | Pelitinib | ≥98% | 257933-82-7 | 5mg,25mg,100mg | EGFR | 3.5 nM | ||
Src | 282 nM | |||||||
MEK/ERK | 800 nM | |||||||
ErbB2 | 1255 nM | |||||||
B126145 | AC480 (BMS-599626) | ≥98% | 714971-09-2 | 5mg,10mg,25mg,100mg | HER1 | 20 nM | ||
HER2 | 30 nM | |||||||
A126830 | AEE788 (NVP-AEE788) | ≥97% | 497839-62-0 | 5mg,25mg,100mg | EGFR | 2 nM | ||
HER2/ErbB2 | 6 nM | |||||||
A127691 | AP26113 | ≥98% | 1197958-12-5 | 5mg,10mg,25mg, | ALK | |||
EGFR | ||||||||
O125033 | OSI-420 | ≥99% | 183320-51-6 | 1mg,5mg,10mg,50mg | EGFR | 2 nM | ||
W127717 | WZ3146 | ≥98% | 1214265-56-1 | 1mg,5mg,25mg,100mg | EGFR(L858R) | 2 nM | ||
EGFR(E746_A750) | 2 nM | |||||||
A126334 | ARRY-380 | ≥98% | 937265-83-3 | 1mg,5mg,10mg,50mg | HER2 | 8 nM | ||
W126471 | WZ8040 | ≥98% | 1214265-57-2 | 1mg,5mg,25mg,50mg | EGFR | |||
A129426 | AST-1306 TsOH | ≥98% | 1050500-29-2 | 5mg,10mg,50mg | EGFR | 0.5 nM | ||
ErbB2 | 3 nM | |||||||
C124905 | CO-1686 (AVL-301) | ≥99% | 1374640-70-6 | 5mg,10mg,50mg,100mg | 无细胞 | EGFRL858R/T790M | 21.5 nM | |
EGFRWT | 303.3 nM | |||||||
G106672 | 金雀异黄酮 | 分析标准品,≥98% | 446-72-0 | 20mg,1g,5g | NIH-3T3细胞 | EGF | 12μM | |
胰岛素 | 19 μM | |||||||
G106673 | 金雀异黄酮 | 97% | 446-72-0 | 100mg,500mg,1g,5g,25g | NIH-3T3细胞 | EGF | 12μM | |
胰岛素 | 19 μM | |||||||
V129433 | Varlitinib | ≥96% | 845272-21-1 | 1mg,5mg,10mg,50mg | ErbB1(EGFR) | 7 nM | ||
ErbB2(HER2) | 2 nM | |||||||
I129405 | Icotinib | ≥99% | 610798-31-7 | 5mg,10mg,50mg | EGFR | 5 nM | ||
T126234 | TAK-285 | ≥98% | 871026-44-7 | 1mg,5mg,10mg,50mg | HER2 | 17 nM | ||
EGFR(HER1) | 23 nM | |||||||
W125072 | WHI-P154 | ≥98% | 211555-04-3 | 10mg,50mg | JAK3 | 1.8 μM | ||
D155111 | Daphnetin | >90.0%(HPLC) | 486-35-1 | 50mg,100mg,250mg,1g | EGFR | 7.67 μM | ||
PKA | 9.33 μM | |||||||
PKC | 25.01 μM | |||||||
P129447 | PD168393 | ≥98% | 194423-15-9 | 10mg,50mg,250mg | EGFR | 0.70 nM | ||
T129439 | Tyrphostin 9 | ≥98% | 10537-47-0 | 25mg,50mg,100mg,500mg | EGFR | 460 μM | ||
PDGFR | 0.5μM | |||||||
T129445 | Tyrphostin 23 | ≥98% | 118409-57-7 | 10mg,50mg,250mg | EGFR | 35 μM | ||
T162509 | 酪氨酸激酶抑制剂 AG 494 | >98.0%(HPLC)(N) | 133550-35-3 | 20mg,100mg | EGFR | 1.2 μM | ||
EGF | 6 μM | |||||||
O173511 | Olmutinib | 97% | 1353550-13-6 | 5mg,100mg | ||||
PD153035 | PD153035 | ≥98% | 153436-54-5 | 10mg,50mg,250mg | EGFR | 5.2 pM | ||
E126691 | EBE-A22 | - | 229476-53-3 | 5mg,10mg,25mg,50mg,100mg | ||||
E107404 | (-)-表没食子儿茶素没食子酸 | 98% | 989-51-5 | 100mg,200mg,2.5g | EGF/HER-2 | |||
E107403 | (-)-表没食子儿茶素没食子酸 | 分析标准品 | 989-51-5 | 20mg,100mg | EGF/HER-2 | |||
E126633 | Erlotinib | ≥98% | 183321-74-6 | 100mg,500mg,1g,5g | EGFR | 2 nM | ||
D101144 | 大黄酚 | 97% | 481-74-3 | 50mg,250mg,1g | EGFR | |||
mTOR | ||||||||
D101143 | 大黄酚 | 分析标准品,≥98% | 481-74-3 | 20mg | EGFR | |||
mTOR | ||||||||
N159736 | Norcantharidin | 98% | 29745-04-8 | 1g,5g,25g | c-Met | |||
EGFR | ||||||||
B135922 | Butein | ≥98.0%(HPLC) | 487-52-5 | 100mg,1g | EGFR |
*HER2
项目号 | 产品名称 | 规格 | CAS | 包装 | 细胞 | 靶点 | IC50 |
---|---|---|---|---|---|---|---|
L129338 | 二对甲苯磺酸拉帕替尼(GW-572016) | ≥98% | 388082-77-7 | 25mg,100mg,250mg,500mg,1g | 无细胞 | ErbB2 | 9.2 nM |
EGFR | 10.8 nM | ||||||
N126132 | Neratinib (HKI-272) | ≥99% | 698387-09-6 | 5mg,25mg,100mg | 无细胞 | HER2 | 59 nM |
EGFR | 92 nM | ||||||
C125447 | Canertinib (CI-1033) | ≥98% | 267243-28-7 | 10mg,50mg,250mg | EGFR | 1.5 nM | |
ErbB2 | 9.0 nM | ||||||
L126696 | Lapatinib | ≥99% | 231277-92-2 | 25mg,100mg,250mg,500mg,1g,5g | ErbB2 | 9.2 nM | |
EGFR | 10.8 nM | ||||||
C129397 | CP-724714 | ≥99% | 537705-08-1 | 5mg,10mg,25mg,50mg | HER2/ErbB2 | 10 nM | |
D129347 | Dacomitinib (PF299804, PF299) | ≥99% | 1110813-31-4 | 5mg,10mg,50mg,250mg | EGFR | 6 nM | |
A129380 | AZD8931 (Sapitinib) | ≥98% | 848942-61-0 | 5mg,10mg,50mg | 无细胞 | EGFR | 4 nM |
ErbB2 | 3 nM | ||||||
ErbB3 | 4 nM | ||||||
C127191 | CUDC-101 | ≥98% | 1012054-59-9 | 10mg,25mg,50mg,10mmg,250mg | HDAC | 4.4 nM | |
EGFR | 2.4 nM | ||||||
HER2 | 15.7 nM | ||||||
M129797 | Mubritinib (TAK 165) | ≥99% | 366017-09-6 | 10mg,50mg,250mg | T-474细胞 | HER2/ErbB2 | 6 nM |
B126145 | AC480 (BMS-599626) | ≥98% | 714971-09-2 | 5mg,10mg,25mg,100mg | HER1 | 20 nM | |
HER2 | 30 nM | ||||||
A126830 | AEE788 (NVP-AEE788) | ≥97% | 497839-62-0 | 5mg,25mg,100mg | EGFR | 2 nM | |
HER2/ErbB2 | 6 nM | ||||||
T126234 | TAK-285 | ≥98% | 871026-44-7 | 1mg,5mg,10mg,50mg | HER2 | 17 nM | |
EGFR(HER1) | 23 nM | ||||||
T129799 | Tyrphostin AG 879 | ≥98% | 148741-30-4 | 5mg,25mg,100mg | HER2/ErbB2 | 1 μM | |
N133726 | 去甲二氢愈创木酸 | ≥95% | 500-38-9 | 1g,5g | IGF-1R/HER2 | ||
L193141 | 二甲苯磺酸拉帕替尼 一水合物 | 0.98 | 388082-78-8 | 1g,5g | EGFR | 10.8 nM | |
ErbB2 | 9.2 nM | ||||||
E107404 | (-)-表没食子儿茶素没食子酸 | 98% | 989-51-5 | 100mg,200mg,2.5g | EGF/HER-2 | ||
E107403 | (-)-表没食子儿茶素没食子酸 | 分析标准品 | 989-51-5 | 20mg,100mg | EGF/HER-2 |
*HIF
产品号 | 产品名称 | 规格 | CAS | 包装 | 细胞 | 靶点 | IC50 |
---|---|---|---|---|---|---|---|
M125960 | 2-Methoxyestradiol (2-MeOE2) | ≥98% | 362-07-2 | 10mg,25mg,50mg,100mg,500mg | |||
P101691 | 芍药苷 | ≥98%(HPLC) | 23180-57-6 | 10mg,500mg,5g | |||
P101690 | 芍药苷 | 分析标准品,≥98% | 23180-57-6 | 20mg | |||
F126178 | FG-4592 | ≥98% | 808118-40-3 | 10mg,50mg,25mg | HIF-α脯氨酰羟化酶 | ||
I127127 | IOX2 | ≥98% | 931398-72-0 | 5mg,25mg,100mg | 无细胞 | PHD2 | 21 nM |
V171541 | Vadadustat | 97% | 1000025-07-9 | 100mg | |||
N170064 | N-acetylcysteine amide | 98% (HPLC) | 38520-57-9 | 5mg,25mg | |||
D136754 | DMOG | ≥98% (HPLC) | 89464-63-1 | 50mg,100mg,250mg,1g | HIF prolyl hydroxylase |
*Bcr-Abl
项目号 | 产品名称 | 规格 | CAS | 包装 | 细胞 | 靶点 | IC50 | ED50 |
---|---|---|---|---|---|---|---|---|
D125110 | Dasatinib | ≥99% | 302962-49-8 | 25mg,100mg,500mg,1g,5g | 无细胞 | Abl | <1 nM | |
Src | 0.8 nM | |||||||
c-Kit | 79 nM | |||||||
I129225 | Imatinib Mesylate (STI571) | ≥99% | 220127-57-1 | 100mg,250mg,1g,5g,25g | v-Abl | 0.6 μM | ||
c-Kit | 0.1 μM | |||||||
PDGFR | 0.1 μM | |||||||
P127550 | Ponatinib (AP24534) | ≥99% | 943319-70-8 | 10mg,50mg,250mg | 无细胞 | Abl | 0.37 nM | |
PDGFRα | 1.1 nM | |||||||
VEGFR2 | 1.5 nM | |||||||
FGFR1 | 2.2 nM | |||||||
Src | 5.4 nM | |||||||
N126111 | Nilotinib (AMN-107) | ≥99% | 641571-10-0 | 25mg,100mg,250mg,1g | 小鼠骨髓祖细胞 | BCR-ABL | <30 nM | |
D126182 | Danusertib (PHA-739358) | ≥98% | 827318-97-8 | 5mg,10mg,50mg | 无细胞 | Aurora A/B/C | 13 nM/79 nM/61 nM | |
Aurora A/B/C | 13 nM/79 nM/61 nM | |||||||
Aurora A/B/C | 13 nM/79 nM/61 nM | |||||||
B129232 | Bafetinib (INNO-406) | ≥98% | 859212-16-1 | 5mg,25mg,100mg | 无细胞 | Bcr-Abl | 5.8 nM | |
Lyn | 19 nM | |||||||
K127169 | KW-2449 | ≥98% | 1000669-72-6 | 5mg,25mg,100mg | Flt3 | 6.6 nM | ||
N127928 | NVP-BHG712 | ≥98% | 940310-85-0 | 5mg,25mg,100mg | EphB4 | 25 nM | ||
c-Raf | 0.395 μM | |||||||
c-Src | 1.266 μM | |||||||
c-Abl | 1.667 μM | |||||||
P126419 | PP121 | ≥98% | 1092788-83-4 | 10mg,50mg | PDGFR | 2 nM | ||
Hck | 8 nM | |||||||
mTOR | 10 nM | |||||||
VEGFR2 | 12 nM | |||||||
Src | 14 nM | |||||||
Abl | 18 nM | |||||||
DNA-PK | 60 nM | |||||||
D126373 | DCC-2036 (Rebastinib) | ≥99% | 1020172-07-9 | 10mg,50mg | Abl1(WT) | 0.8 nM | ||
Abl1(T315I) | 4 nM | |||||||
G129296 | GZD824 | ≥99% | 1421783-64-3 | 5mg,25mg | Bcr-Abl(WT) | 0.34 nM | ||
Bcr-Abl(T315I) | 0.68 nM | |||||||
G126166 | GNF-2 | ≥98% | 778270-11-4 | 5mg,25mg,50mg,250mg | Bcr-Abl | |||
G177569 | GNF-7 | 97% | 839706-07-9 | 100mg | M351T | <5 nM | ||
T315I | 61 nM | |||||||
E255 V | 122 nM | |||||||
G250E | 136 nM | |||||||
c-Abl | 133 nM |
*FAK
项目号 | 产品名称 | 规格 | CAS | 包装 | 细胞 | 靶点 | IC50 |
---|---|---|---|---|---|---|---|
P129811 | PF-00562271 | ≥97% | 939791-38-5 | 5mg,10mg,50mg | FAK | 1.5 nM | |
P126147 | PF-562271 | ≥98% | 717907-75-0 | 5mg,10mg,50mg,100mg | FAK | 1.5 nM | |
P129908 | PRT062607 (P505-15, BIIB057) HCl | ≥98% | 1370261-97-4 | 5mg,25mg | 无细胞 | Syk | 1 nM |
P129814 | PF-573228 | ≥98% | 869288-64-2 | 10mg,50mg | 无细胞 | FAK | 4 nM |
T129808 | TAE226 (NVP-TAE226) | ≥99% | 761437-28-9 | 5mg,10mg,50mg | FAK | 5.5 nM | |
P127543 | PF-03814735 | ≥99% | 942487-16-3 | 1mg,5mg,10mg,50mg | Aurora A | 0.8 nM | |
Aurora B | 0.5 nM | ||||||
P126394 | PND-1186 | ≥98% | 1061353-68-1 | 5mg,25mg,100mg | FAK | 1.5 nM | |
P127348 | PF-431396 | ≥98% | 717906-29-1 | 10mg,50mg | PYK2 | 11nM | |
FAK | 2 nM |
*ALK
项目号 | 产品名称 | 规格 | CAS | 包装 | 细胞 | 靶点 | IC50 | Ki |
---|---|---|---|---|---|---|---|---|
C137735 | Crizotinib | ≥99% | 877399-52-5 | 10mg,50mg,100mg,250mg,500mg,1g,5g | 无细胞 | c-Met | 11 nM | |
ALK | 24 nM | |||||||
T129819 | TAE684 (NVP-TAE684) | ≥98% | 761439-42-3 | 5mg,10mg,50mg | 无细胞 | ALK | 3 nM | |
C125242 | CH5424802 | ≥98% | 1256580-46-7 | 5mg,25mg,100mg | 无细胞 | ALK | 1.9 nM | |
L127618 | LDK378 | ≥99% | 1032900-25-6 | 5mg,25mg,100mg,250mg | 无细胞 | ALK | 0.2 nM | |
A127691 | AP26113 | ≥98% | 1197958-12-5 | 5mg,10mg,25mg,50mg,100mg | ALK | |||
EGFR | ||||||||
A125664 | AZD3463 | ≥98% | 1356962-20-3 | 5mg,25mg,100mg | ALK | 0.75 nM | ||
A128022 | ASP3026 | ≥98% | 1097917-15-1 | 5mg,25mg,100mg | ALK | 3.5 nM | ||
P167337 | PF-06463922 acetate | 98% (HPLC) | 1454846-35-5 | 5mg | ROS1 | <0.02 nM | ||
ALK (WT) | <0.07 nM | |||||||
ALK (L1196M) | 0.7 nM |
*FGFR
产品号 | 产品名称 | 规格 | CAS | 包装 | 细胞 | 靶点 | IC50 |
---|---|---|---|---|---|---|---|
S129593 | Sorafenib Tosylate | ≥99% | 475207-59-1 | 10mg,50mg,250mg,1g,5g | 无细胞 | Raf-1 | 6 nM |
B-Raf | 22 nM | ||||||
VEGFR-2 | 90 nM | ||||||
VEGFR-3 | 20 nM | ||||||
PDGFR-β | 57 nM | ||||||
Flt-3 | 59 nM | ||||||
c-KIT | 68 nM | ||||||
P127550 | Ponatinib (AP24534) | ≥99% | 943319-70-8 | 10mg,50mg,250mg | 无细胞 | Abl | 0.37 nM |
PDGFRα | 1.1 nM | ||||||
VEGFR2 | 1.5 nM | ||||||
FGFR1 | 2.2 nM | ||||||
Src | 5.4 nM | ||||||
N127052 | BGJ398 (NVP-BGJ398) | ≥98% | 872511-34-7 | 5mg,25mg,10mg | 无细胞 | FGFR1 | 0.9 nM |
FGFR2 | 1.4 nM | ||||||
FGFR3 | 1 nM | ||||||
N129725 | Nintedanib (BIBF 1120) | ≥98% | 656247-17-5 | 5mg,10mg,25mg,50mg,100mg,500mg | 无细胞 | VEGFR1 | 34 nM |
VEGFR2 | 13 nM | ||||||
VEGFR3 | 13 nM | ||||||
FGFR1 | 69 nM | ||||||
FGFR2 | 37 nM | ||||||
FGFR3 | 108 nM | ||||||
PDGFRα | 59 nM | ||||||
PDGFRβ | 65 nM | ||||||
P129722 | Pazopanib HCl (GW786034 HCl) | ≥98% | 635702-64-6 | 25mg,100mg,250mg,1g | 无细胞 | VEGFR1 | 10 nM |
VEGFR2 | 30 nM | ||||||
VEGFR3 | 47 nM | ||||||
PDGFR | 84 nM | ||||||
FGFR | 74 nM | ||||||
c-Kit | 140 nM | ||||||
c-fms | 146 nM | ||||||
P125865 | PD173074 | ≥99% | 219580-11-7 | 5mg,10mg,50mg | FGFR1 | 25 nM | |
VEGFR2 | 100-200 nM | ||||||
D126778 | Dovitinib (TKI-258, CHIR-258) | ≥99% | 405169-16-6 | 10mg,50mg,250mg | 无细胞 | FLT3 | 1 nM |
c-Kit | 2 nM | ||||||
A127209 | AZD4547 | ≥99% | 1035270-39-3 | 5mg,10mg,25mg,50mg,100mg | 无细胞 | FGFR1 | 0.2 nM |
FGFR2 | 2.5 nM | ||||||
FGFR3 | 1.8 nM | ||||||
D126182 | Danusertib (PHA-739358) | ≥98% | 827318-97-8 | 1mg,5mg,10mg,50mg | 无细胞 | Aurora A | 13 nM |
Aurora B | 79 nM | ||||||
Aurora C | 61 nM | ||||||
L125518 | Lenvatinib (E7080) | ≥99% | 417716-92-8 | 5mg,10mg,50mg,100mg | 无细胞 | VEGFR2/KDR | 4.0 nM |
VEGFR3/FLT4 | 5.2 nM | ||||||
B127317 | Brivanib (BMS-540215) | ≥98% | 649735-46-6 | 5mg,10mg,50mg | VEGFR2 | 25 nM | |
E126318 | ENMD-2076 | ≥99% | 934353-76-1 | 5mg,10mg,50mg | Aurora A | 14 nM | |
Flt3 | 1.86 nM | ||||||
P125184 | Pazopanib | ≥99% | 444731-52-6 | 25mg,100mg,500mg | GFR1 | 10 nM | |
VEGFR2 | 30 nM | ||||||
VEGFR3 | 47 nM | ||||||
PDGFR | 84 nM | ||||||
FGFR | 74 nM | ||||||
c-Kit | 140 nM | ||||||
c-Fms/CSF1R | 146 nM | ||||||
M129777 | MK-2461 | ≥99% | 917879-39-1 | 1mg,5mg,10mg,50mg | c-Met(WT/mutants) | 0.4-2.5 nM | |
B129764 | Brivanib Alaninate (BMS-582664) | ≥95% | 649735-63-7 | 10mg,50mg | VEGFR2 | 25 nM | |
T129775 | Tyrphostin AG 1296 | ≥99% | 146535-11-7 | 1mg,5mg,25mg | PDGFR | 0.3-0.5 μM | |
Swiss 3T3细胞 | FGFR | 12.3 μM | |||||
c-Kit | 1.8 μM | ||||||
L126507 | LY2874455 | ≥99% | 1254473-64-7 | 5mg,10mg,50mg | FGFR1 | 2.8 nM | |
FGFR2 | 2.6 nM | ||||||
FGFR3 | 6.4 nM | ||||||
FGFR4 | 6 nM | ||||||
VEGFR2 | 7 nM | ||||||
F103701 | 阿魏酸 | 99% | 1135-24-6 | 5g,10g,25g,50g,100g,250g,500g,1kg | |||
F103702 | 阿魏酸 | 分析标准品,≥99.5%(HPLC) | 1135-24-6 | 20mg | |||
O173545 | ON-123300 | 97% | 1357470-29-1 | 5mg,100mg | CDK4 | 3.9 nM | |
Ark5/NUAK1 | 5 nM | ||||||
PDGFRβ | 26 nM | ||||||
FGFR1 | 26 nM | ||||||
RET | 9.2 nM | ||||||
Fyn | 11nM | ||||||
P132694 | PD-166866 | ≥98%(HPLC) | 192705-79-6 | 5mg,25mg,100mg | FGFR1 | 52.4 nM | |
B174512 | BLU-9931 | 97% | 1538604-68-0 | 5mg,100mg | FGFR4 | 3 nM |
更多
重组抗体 | 携手阿拉丁,共创科研新高度
厂商
2024.08.22
【阿拉丁】Caspase免疫荧光染色方案
厂商
2024.08.20
阿拉丁标签抗体 | 特异性识别,助力科学发现
厂商
2024.08.12
阿拉丁药靶抗体 | 癌症治疗的明星分子
厂商
2024.08.08